Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

BACKGROUND: The MEK1/2 inhibitor selumetinib was recently approved for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but outcomes could be improved and its pharmacodynamic evaluation in other relevant tissues is limited. The aim of this study was to assess selumetinib tissue pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Osum, Sara H, Coutts, Alexander W, Duerre, Dylan J, Tschida, Barbara R, Kirstein, Mark N, Fisher, James, Bell, W Robert, Delpuech, Oona, Smith, Paul D, Widemann, Brigitte C, Moertel, Christopher L, Largaespada, David A, Watson, Adrienne L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095338/
https://www.ncbi.nlm.nih.gov/pubmed/33978635
http://dx.doi.org/10.1093/noajnl/vdab020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095338/
https://www.ncbi.nlm.nih.gov/pubmed/33978635
http://dx.doi.org/10.1093/noajnl/vdab020

Ejemplares similares